Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Recruiting · NCT04691817 · Interventional (participants receive a specific treatment) · Lead sponsor: Abramson Cancer Center at Penn Medicine
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to at least 1 line of therapy
- Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ECOG PS 0-2
Exclusion criteria
- Presence of a driver mutation that is susceptible to targeted therapy
- No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
- Other active invasive malignancy requiring ongoing therapy
- Evidence of progressing or untreated brain metastases
- Evidence or history of leptomeningeal disease
- Uncontrolled tumor related pain
- History of an autoimmune disease or IPF
Where it is running
1 location listed across 1 US state.
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia, Pennsylvania, United States